FDA Drug Error Effort By Safety Office Builds On Existing Agency Activities
This article was originally published in The Tan Sheet
Executive Summary
FDA's new office of drug safety provides a formal structure for the agency's existing medication error activities, Office of Postmarketing Drug Risk Assessment Deputy Director Ralph Lillie told an Oct. 27 meeting of the Regulatory Affairs Professionals Society in Washington, D.C.